{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:18:40Z","timestamp":1790788720738,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In patients with presumed primary CNS lymphoma (PCNSL), a systemic manifestation is found only in a small minority. Although bone marrow biopsy (BMB) is recommended for staging, its diagnostic value is unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective analysis of 392 patients with presumed PCNSL from 3 university hospitals and 33 patients with secondary CNS lymphoma (SCNSL) and initial CNS involvement from a multicenter Germany-wide prospective registry was performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A BMB was performed and documented in 320\/392 patients with presumed PCNSL; 23 had pathologic results. One harbored the same lymphoma in the brain and bone marrow (BM), 22 showed findings in BM discordant to the histology of brain lymphoma; n = 12 harbored a low-grade lymphoma in the BM, the other showed B-cell proliferation but no proof of lymphoma (n = 5), monoclonal B cells (n = 3), or abnormalities not B-cell-associated (n = 2). In the group of SCNSL with initial CNS manifestation, 32\/33 patients underwent BMB; 7 were documented with bone marrow involvement (BMI); 1 had concordant results in the brain and BM with no other systemic manifestation. Six had additional systemic lymphoma manifestations apart from the brain and BM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In only 2 out of 352 (0.6%) patients with CNS lymphoma (320 presumed PCNSL and 32 SCNSL), BMB had an impact on diagnosis and treatment. While collected in a selected cohort, these findings challenge the value of BMB as part of routine staging in presumed PCNSL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noab109","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T11:08:13Z","timestamp":1620558493000},"page":"2076-2084","source":"Crossref","is-referenced-by-count":15,"title":["The value of bone marrow biopsy for staging of patients with primary CNS lymphoma"],"prefix":"10.1093","volume":"23","author":[{"given":"Michelle","family":"Margold","sequence":"first","affiliation":[{"name":"Department of Neurology, Knappschaftskrankenhaus University of Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Seidel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Knappschaftskrankenhaus University of Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kowalski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Knappschaftskrankenhaus University of Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetlana","family":"Ladigan-Badura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Knappschaftskrankenhaus University of Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Baraniskin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Knappschaftskrankenhaus University of Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schroers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Knappschaftskrankenhaus University of Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Verena","family":"Frey","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo G H","family":"Schmidt-Wolf","sequence":"additional","affiliation":[{"name":"Department of Integrated Oncology, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Herrlinger","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Korfel","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Charit\u00e9 University of Berlin, Campus Benjamin Franklin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Schlegel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Knappschaftskrankenhaus University of Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"2021120505421322100_CIT0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"2021120505421322100_CIT0002","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF01054724","article-title":"Occult systemic non-Hodgkin\u2019s lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?","volume":"25","author":"O\u2019Neill","year":"1995","journal-title":"J Neurooncol."},{"issue":"5","key":"2021120505421322100_CIT0003","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<827::AID-CNCR4>3.0.CO;2-B","article-title":"Importance of complete staging in non-Hodgkin\u2019s lymphoma presenting as a cerebral mass lesion","volume":"77","author":"Ferreri","year":"1996","journal-title":"Cancer."},{"issue":"22","key":"2021120505421322100_CIT0004","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol."},{"issue":"7","key":"2021120505421322100_CIT0005","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol."},{"issue":"3","key":"2021120505421322100_CIT0006","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1006250317940","article-title":"Primary CNS lymphoma: findings outside the brain","volume":"43","author":"Herrlinger","year":"1999","journal-title":"J Neurooncol."},{"issue":"3","key":"2021120505421322100_CIT0007","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jamaneurol.2013.606","article-title":"A systematic approach to the diagnosis of suspected central nervous system lymphoma","volume":"70","author":"Scott","year":"2013","journal-title":"JAMA Neurol."},{"issue":"25","key":"2021120505421322100_CIT0008","first-page":"419","article-title":"The diagnosis and treatment of primary CNS lymphoma","volume":"115","author":"von Baumgarten","year":"2018","journal-title":"Dtsch Arztebl Int."},{"issue":"1","key":"2021120505421322100_CIT0009","first-page":"17","article-title":"Primary central nervous system lymphoma - part 1: epidemiology, diagnosis, staging, and prognosis","volume":"32","author":"Lukas","year":"2018","journal-title":"Oncology (Williston Park)."},{"key":"2021120505421322100_CIT0010","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/EDBK_242547","article-title":"Evolving treatments for primary central nervous system lymphoma","volume":"39","author":"Ferreri","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"2021120505421322100_CIT0011","doi-asserted-by":"crossref","first-page":"iv144","DOI":"10.1093\/annonc\/mdu330.24","article-title":"Role of bone marrow evaluation (BME) in Primary Central Nervous System Lymphoma (PCNSL) in a multiracial Asian population","volume":"25","author":"Wong","year":"2014","journal-title":"Ann Oncol."},{"issue":"2","key":"2021120505421322100_CIT0012","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/10428194.2018.1482538","article-title":"A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells","volume":"60","author":"Brandt","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"4","key":"2021120505421322100_CIT0013","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood-2007-01-070300","article-title":"Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index","volume":"110","author":"Chung","year":"2007","journal-title":"Blood."},{"issue":"11","key":"2021120505421322100_CIT0014","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2010.33.3419","article-title":"Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP","volume":"29","author":"Sehn","year":"2011","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021120505421322100_CIT0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jclinpath-2012-201158","article-title":"Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP","volume":"66","author":"Shim","year":"2013","journal-title":"J Clin Pathol."},{"issue":"9","key":"2021120505421322100_CIT0016","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/jclinpath-2014-202656","article-title":"Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"68","author":"Park","year":"2015","journal-title":"J Clin Pathol."},{"issue":"16","key":"2021120505421322100_CIT0017","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.2019000858","article-title":"Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma","volume":"134","author":"Wang","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2021120505421322100_CIT0018","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/leu.2017.222","article-title":"Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy","volume":"32","author":"Yao","year":"2018","journal-title":"Leukemia."},{"issue":"1","key":"2021120505421322100_CIT0019","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hon.953","article-title":"Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome","volume":"29","author":"Chigrinova","year":"2011","journal-title":"Hematol Oncol."},{"issue":"6","key":"2021120505421322100_CIT0020","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1046\/j.1365-2141.2003.04329.x","article-title":"Bone marrow biopsy morbidity and mortality","volume":"121","author":"Bain","year":"2003","journal-title":"Br J Haematol."},{"issue":"10","key":"2021120505421322100_CIT0021","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2015.126656","article-title":"Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell","volume":"100","author":"Malecka","year":"2015","journal-title":"Haematologica."},{"issue":"1","key":"2021120505421322100_CIT0022","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.LAB.0000050762.61660.27","article-title":"Discordant bone marrow involvement in diffuse large B-cell lymphoma: comparative molecular analysis reveals a heterogeneous group of disorders","volume":"83","author":"Kremer","year":"2003","journal-title":"Lab Invest."},{"issue":"29","key":"2021120505421322100_CIT0023","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1200\/JCO.2006.06.7165","article-title":"Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes","volume":"24","author":"Jahnke","year":"2006","journal-title":"J Clin Oncol."},{"issue":"19","key":"2021120505421322100_CIT0024","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood-2008-09-179366","article-title":"Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development","volume":"113","author":"McCann","year":"2009","journal-title":"Blood."},{"issue":"1","key":"2021120505421322100_CIT0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/hon.944","article-title":"Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series","volume":"29","author":"Provencher","year":"2011","journal-title":"Hematol Oncol."},{"issue":"2","key":"2021120505421322100_CIT0026","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.medcli.2019.07.022","article-title":"Whole body FDG-PET\/CT for the assessment of bone marrow infiltration in patients with newly diagnosed lymphoma","volume":"154","author":"Xiao-Xue","year":"2020","journal-title":"Med Clin (Barc)."},{"issue":"5","key":"2021120505421322100_CIT0027","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00277-011-1353-6","article-title":"Role of FDG-PET\/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma","volume":"91","author":"Hong","year":"2012","journal-title":"Ann Hematol."},{"issue":"2","key":"2021120505421322100_CIT0028","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11060-020-03525-5","article-title":"Use of FDG-PET\/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study","volume":"148","author":"Bertaux","year":"2020","journal-title":"J Neurooncol."},{"issue":"5","key":"2021120505421322100_CIT0029","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"2021120505421322100_CIT0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noab109\/38837008\/noab109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/12\/2076\/41429780\/noab109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/12\/2076\/41429780\/noab109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T05:43:18Z","timestamp":1638682998000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/12\/2076\/6275308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,5,13]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab109","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,5,13]]}}}